Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Second cancers in MPN: Survival analysis from an international study

M. Marchetti, A. Ghirardi, A. Masciulli, A. Carobbio, F. Palandri, N. Vianelli, E. Rossi, S. Betti, A. Di Veroli, A. Iurlo, D. Cattaneo, G. Finazzi, M. Bonifacio, L. Scaffidi, A. Patriarca, E. Rumi, IC. Casetti, C. Stephenson, P. Guglielmelli,...

. 2020 ; 95 (3) : 295-301. [pub] 20191222

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, časopisecké články, multicentrická studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20023120

One out of ten patients with Philadelphia-negative myeloproliferative neoplasms (MPN) develop a second cancer (SC): in such patients we aimed at assessing the survival impact of SC itself and of MPN-specific therapies. Data were therefore extracted from an international nested case-control study, recruiting 798 patients with SC diagnosed concurrently or after the MPN. Overall, 2995 person-years (PYs) were accumulated and mortality rate (MR) since SC diagnosis was 5.9 (5.1-6.9) deaths for every 100 PYs. A "poor prognosis" SC (stomach, esophagus, liver, pancreas, lung, ovary, head-and-neck or nervous system, osteosarcomas, multiple myeloma, aggressive lymphoma, acute leukemia) was reported in 26.3% of the patients and was the cause of death in 65% of them (MR 11.0/100 PYs). In contrast, patients with a "non-poor prognosis" SC (NPPSC) incurred a MR of 4.6/100 PYs: 31% of the deaths were attributed to SC and 15% to MPN evolution. At multivariable analysis, death after SC diagnosis was independently predicted (HR and 95% CI) by patient age greater than 70 years (2.68; 1.88-3.81), the SC prognostic group (2.57; 1.86-3.55), SC relapse (1.53; 10.6-2.21), MPN evolution (2.72; 1.84-4.02), anemia at SC diagnosis (2.32; 1.49-3.59), exposure to hydroxyurea (1.89; 1.26-2.85) and to ruxolitinib (3.63; 1.97-6.71). Aspirin was protective for patients with a NPPSC (0.60; 0.38-0.95). In conclusion, SC is a relevant cause of death competing with MPN evolution. Prospective data are awaited to confirm the role of cytoreductive and anti-platelet drugs in modulating patient survival after the occurrence of a SC.

Center for Translational and Clinical Research Aachen University Hospital RWTH Aachen Aachen Germany

Centre for Medical Education Queen's University Belfast Belfast UK

CRIMM Center of Research and Innovation of Myeloproliferative Neoplasms Azienda Ospedaliera Universitaria Careggi Firenze Italy Department Experimental and Clinical Medicine University of Florence Firenze Italy

Deparment of Hematology Hospital Clínico Universitario de Santiago de Compostela Santiago de Compostela Spain

Department of Hemato oncology University Hospital Olomouc Olomouc Czech Republic

Department of Hematology Hospital Clínic Barcelona Spain

Department of Hematology Hospital Clínico Universitario Valencia Spain

Department of Hematology Hospital del Mar Barcelona Spain

Department of Hematology Hospital Universitario Miguel Servet Zaragoza Spain

Department of Hematology Hospital Universitario Vall d'Hebron Barcelona Spain

Department of Hematology Oncology Fondazione IRCCS Policlinico San Matteo Pavia Pavia Italy Department of Molecular Medicine University of Pavia Pavia Italy

Department of Medicine and Surgery Hematology and Hematopoietic Stem Cell Transplant Center University of Naples Federico 2 Naples Italy

Department of Medicine Section of Hematology University of Verona Verona Italy

Department of Molecular Medicine University of Pavia Pavia Italy

Division of Hematology Città della Salute e della Scienza Hospital Torino Italy

Division of Hematology Department of Translational Medicine University of Eastern Piedmont Novara Italy

Division of Hematology Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico and University of Milan Milan Italy

Division of Hematology Ospedale San Gerardo ASST Monza Italy

Division of Hematology Papa Giovanni XXIII Hospital Bergamo Italy

Division of Hematology San Bortolo Hospital Vicenza Italy

Fondazione Policlinico Universitario A Gemelli IRCCS Rome Italy

FROM Research Foundation Papa Giovanni XXIII Hospital Bergamo Italy

Guy's and St Thomas' NHS Foundation Trust London UK

Haemostasis Unit Department of Clinical and Experimental Medicine University of Catania Policlinico Vittorio Emanuele Hospital Catania Italy

Hematology and Bone Marrow Transplantation Unit IRCCS San Raffaele Scientific Institute Milan Italy

Hematology Institute and Blood Bank Meir Medical Center Kfar Saba Israel Sackler School of Medicine Tel Aviv University Tel Aviv Israel

Hematology Unit Azienda Unità Sanitaria Locale IRCCS di Reggio Emilia Reggio Emilia Italy

Institute of Hematology Catholic University Rome Italy Fondazione Policlinico Universitario A Gemelli IRCCS Rome Italy

Institute of Hematology L and A Seràgnoli S Orsola Malpighi Hospital Bologna Italy

Oncology Unit Cardinal Massaia Hospital Asti Italy

Rete Laziale MPN Rome Italy

S C Ematologia Azienda Ospedaliera S Croce e Carle Cuneo Italy

Unit of Hematology Department of Oncology University of Torino Torino Italy

University Clinic for Hematology and Oncology Minden University of Bochum Minden Germany

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20023120
003      
CZ-PrNML
005      
20240516121827.0
007      
ta
008      
201125s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/ajh.25700 $2 doi
035    __
$a (PubMed)31816122
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Marchetti, Monia $u Oncology Unit, Cardinal Massaia Hospital, Asti, Italy.
245    10
$a Second cancers in MPN: Survival analysis from an international study / $c M. Marchetti, A. Ghirardi, A. Masciulli, A. Carobbio, F. Palandri, N. Vianelli, E. Rossi, S. Betti, A. Di Veroli, A. Iurlo, D. Cattaneo, G. Finazzi, M. Bonifacio, L. Scaffidi, A. Patriarca, E. Rumi, IC. Casetti, C. Stephenson, P. Guglielmelli, EM. Elli, M. Palova, D. Rapezzi, D. Erez, M. Gomez, K. Wille, M. Perez-Encinas, F. Lunghi, A. Angona, ML. Fox, E. Beggiato, G. Benevolo, G. Carli, R. Cacciola, MF. McMullin, A. Tieghi, V. Recasens, S. Isfort, F. Pane, V. De Stefano, M. Griesshammer, A. Alvarez-Larran, AM. Vannucchi, A. Rambaldi, T. Barbui,
520    9_
$a One out of ten patients with Philadelphia-negative myeloproliferative neoplasms (MPN) develop a second cancer (SC): in such patients we aimed at assessing the survival impact of SC itself and of MPN-specific therapies. Data were therefore extracted from an international nested case-control study, recruiting 798 patients with SC diagnosed concurrently or after the MPN. Overall, 2995 person-years (PYs) were accumulated and mortality rate (MR) since SC diagnosis was 5.9 (5.1-6.9) deaths for every 100 PYs. A "poor prognosis" SC (stomach, esophagus, liver, pancreas, lung, ovary, head-and-neck or nervous system, osteosarcomas, multiple myeloma, aggressive lymphoma, acute leukemia) was reported in 26.3% of the patients and was the cause of death in 65% of them (MR 11.0/100 PYs). In contrast, patients with a "non-poor prognosis" SC (NPPSC) incurred a MR of 4.6/100 PYs: 31% of the deaths were attributed to SC and 15% to MPN evolution. At multivariable analysis, death after SC diagnosis was independently predicted (HR and 95% CI) by patient age greater than 70 years (2.68; 1.88-3.81), the SC prognostic group (2.57; 1.86-3.55), SC relapse (1.53; 10.6-2.21), MPN evolution (2.72; 1.84-4.02), anemia at SC diagnosis (2.32; 1.49-3.59), exposure to hydroxyurea (1.89; 1.26-2.85) and to ruxolitinib (3.63; 1.97-6.71). Aspirin was protective for patients with a NPPSC (0.60; 0.38-0.95). In conclusion, SC is a relevant cause of death competing with MPN evolution. Prospective data are awaited to confirm the role of cytoreductive and anti-platelet drugs in modulating patient survival after the occurrence of a SC.
650    _2
$a věkové faktory $7 D000367
650    _2
$a senioři $7 D000368
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a hematologické nádory $x mortalita $7 D019337
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a myeloproliferativní poruchy $x mortalita $7 D009196
650    _2
$a sekundární malignity $x mortalita $7 D016609
650    _2
$a míra přežití $7 D015996
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Ghirardi, Arianna $u FROM Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy.
700    1_
$a Masciulli, Arianna $u FROM Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy.
700    1_
$a Carobbio, Alessandra $u FROM Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy.
700    1_
$a Palandri, Francesca $u Institute of Hematology "L. and A. Seràgnoli", S. Orsola-Malpighi Hospital, Bologna, Italy.
700    1_
$a Vianelli, Nicola $u Institute of Hematology "L. and A. Seràgnoli", S. Orsola-Malpighi Hospital, Bologna, Italy.
700    1_
$a Rossi, Elena $u Institute of Hematology, Catholic University, Rome, Italy. Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
700    1_
$a Betti, Silvia $u Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
700    1_
$a Di Veroli, Ambra $u Rete Laziale MPN, Rome, Italy.
700    1_
$a Iurlo, Alessandra $u Division of Hematology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, and University of Milan, Milan, Italy.
700    1_
$a Cattaneo, Daniele $u Division of Hematology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, and University of Milan, Milan, Italy.
700    1_
$a Finazzi, Guido $u Division of Hematology, Papa Giovanni XXIII Hospital, Bergamo, Italy.
700    1_
$a Bonifacio, Massimiliano $u Department of Medicine, Section of Hematology, University of Verona, Verona, Italy.
700    1_
$a Scaffidi, Luigi $u Department of Medicine, Section of Hematology, University of Verona, Verona, Italy.
700    1_
$a Patriarca, Andrea $u Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.
700    1_
$a Rumi, Elisa $u Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo Pavia, Pavia, Italy. Department of Molecular Medicine, University of Pavia, Pavia, Italy.
700    1_
$a Casetti, Ilaria Carola $u Department of Molecular Medicine, University of Pavia, Pavia, Italy.
700    1_
$a Stephenson, Clemency $u Guy's and St Thomas' NHS Foundation Trust, London, UK.
700    1_
$a Guglielmelli, Paola $u CRIMM-Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy. Department Experimental and Clinical Medicine, University of Florence, Firenze, Italy.
700    1_
$a Elli, Elena Maria $u Division of Hematology, Ospedale San Gerardo, ASST, Monza, Italy.
700    1_
$a Palova, Miroslava $u Department of Hemato-oncology, University Hospital Olomouc, Olomouc, Czech Republic.
700    1_
$a Rapezzi, Davide $u S.C. Ematologia, Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy.
700    1_
$a Erez, Daniel $u Hematology Institute and Blood Bank, Meir Medical Center, Kfar Saba, Israel. Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
700    1_
$a Gomez, Montse $u Department of Hematology, Hospital Clínico Universitario, Valencia, Spain.
700    1_
$a Wille, Kai $u University Clinic for Hematology and Oncology Minden, University of Bochum, Minden, Germany.
700    1_
$a Perez-Encinas, Manuel $u Deparment of Hematology, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain.
700    1_
$a Lunghi, Francesca $u Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
700    1_
$a Angona, Anna $u Department of Hematology, Hospital del Mar, Barcelona, Spain.
700    1_
$a Fox, Maria Laura $u Department of Hematology, Hospital Universitario Vall d'Hebron, Barcelona, Spain.
700    1_
$a Beggiato, Eloise $u Unit of Hematology, Department of Oncology, University of Torino, Torino, Italy.
700    1_
$a Benevolo, Giulia $u Division of Hematology, Città della Salute e della Scienza Hospital, Torino, Italy.
700    1_
$a Carli, Giuseppe $u Division of Hematology, San Bortolo Hospital, Vicenza, Italy.
700    1_
$a Cacciola, Rossella $u Haemostasis Unit, Department of Clinical and Experimental Medicine, University of Catania, "Policlinico-Vittorio Emanuele" Hospital, Catania, Italy.
700    1_
$a McMullin, Mary Frances $u Centre for Medical Education, Queen's University Belfast, Belfast, UK.
700    1_
$a Tieghi, Alessia $u Hematology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
700    1_
$a Recasens, Valle $u Department of Hematology, Hospital Universitario Miguel Servet, Zaragoza, Spain.
700    1_
$a Isfort, Susanne $u Center for Translational & Clinical Research Aachen (CTC-A), University Hospital RWTH Aachen, Aachen, Germany.
700    1_
$a Pane, Fabrizio $u Department of Medicine and Surgery, Hematology and Hematopoietic Stem Cell Transplant Center, University of Naples Federico II, Naples, Italy.
700    1_
$a De Stefano, Valerio $u Institute of Hematology, Catholic University, Rome, Italy. Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
700    1_
$a Griesshammer, Martin $u University Clinic for Hematology and Oncology Minden, University of Bochum, Minden, Germany.
700    1_
$a Alvarez-Larran, Alberto $u Department of Hematology, Hospital Clínic, Barcelona, Spain.
700    1_
$a Vannucchi, Alessandro Maria $u CRIMM-Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy. Department Experimental and Clinical Medicine, University of Florence, Firenze, Italy.
700    1_
$a Rambaldi, Alessandro $u Division of Hematology, Papa Giovanni XXIII Hospital, Bergamo, Italy. $7 xx0317376
700    1_
$a Barbui, Tiziano $u FROM Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy.
773    0_
$w MED00000251 $t American journal of hematology $x 1096-8652 $g Roč. 95, č. 3 (2020), s. 295-301
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31816122 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20240516121821 $b ABA008
999    __
$a ok $b bmc $g 1595439 $s 1113796
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 95 $c 3 $d 295-301 $e 20191222 $i 1096-8652 $m American journal of hematology $n Am J Hematol $x MED00000251
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Možnosti archivace